HansBiomed Corporation (KOSDAQ:042520)

Market Cap	358.44B
Revenue (ttm)	89.78B
Net Income (ttm)	-31.34B
Shares Out	12.99M
EPS (ttm)	-2,413.29
PE Ratio	n/a
Forward PE	33.82
Dividend	n/a
Ex-Dividend Date	n/a

Volume	135,076
Average Volume	459,282
Open	30,100
Previous Close	30,100
Day's Range	29,100 - 30,450
52-Week Range	6,180 - 38,000
Beta	2.10
RSI	41.34
Earnings Date	Dec 19, 2025

About HansBiomed

HansBiomed Corporation, together with its subsidiaries, engages in the research and development, production, and sale of medical materials for the procedure and the raw materials for medical supplies. The company provides ExFuse, a demineralized bone matrix with cancellous bone gel/putty; BellaFuse, a demineralized bone matrix; Genesis, a cancellous sponge block/filler; Pedi-Stick, a demineralized cortical bone stick; SureChip, a cancellous bone chip; OsteoGrow, a demineralized bone matrix inserter; BellaCell HD, an allograft dermal product tha...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1990
• Employees: 277
• Stock Exchange: KOSDAQ
• Ticker Symbol: 042520

Financial Performance

In 2025, HansBiomed's revenue was 89.78 billion, an increase of 10.65% compared to the previous year's 81.14 billion. Losses were -31.34 billion, 333.9% more than in 2024.